P-052A phase 3 study of chemotherapy + pembrolizumab versus chemotherapy + placebo as first-line therapy for patients with advanced esophageal or esophagogastric junction (E/EGJ) cancer: KEYNOTE-590 - Trial in progress. (20th June 2018) - Kato, K; Shah, M; Enzinger, P; Bennouna, J; Shen, L; Adenis, A; Sun, J; Cho, B; Ozguroglu, M; Kojima, T; Kostorov, V; Hierro, C; et al.